BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3991931)

  • 21. Therapeutic drug monitoring. Pharmacokinetic and pharmacodynamic principles.
    Howanitz JH; Howanitz PJ
    Clin Lab Med; 1981 Sep; 1(3):467-78. PubMed ID: 7346215
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical pharmacokinetics in the drug regulatory process.
    Salmonson T; Rane A
    Clin Pharmacokinet; 1990 Mar; 18(3):177-83. PubMed ID: 2323153
    [No Abstract]   [Full Text] [Related]  

  • 23. [Species differences in pharmaco-kinetics of chemicals. Correlations with toxicity (author's transl)].
    Keck G
    Toxicol Eur Res; 1981 Jul; 3(4):207-15. PubMed ID: 7302948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).
    Besunder JB; Reed MD; Blumer JL
    Clin Pharmacokinet; 1988 Apr; 14(4):189-216. PubMed ID: 3292100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biotransformation and pharmacokinetics of mesionic didehydro-4-methyl-5-phenyl-1,3,4-thiadiazolidine-2-thione (LU 2443). Studies on the pharmacokinetics in rats].
    Neidlein R; Eder T
    Arzneimittelforschung; 1982; 32(11):1447-52. PubMed ID: 6891252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable drug responses in man.
    Hunninghake DB
    Postgrad Med; 1972 Apr; 51(4):156-61. PubMed ID: 5027879
    [No Abstract]   [Full Text] [Related]  

  • 27. [Ambroxol, comparative studies of pharmacokinetics and biotransformation in rat, rabbit, dog and man (author's transl)].
    Hammer R; Bozler G; Jauch R; Koss FW; Hadamovsky H
    Arzneimittelforschung; 1978; 28(5a):899-903. PubMed ID: 581988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of the dog in toxicity tests on pharmaceutical compounds.
    Parkinson C; Grasso P
    Hum Exp Toxicol; 1993 Mar; 12(2):99-109. PubMed ID: 8096722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Characteristics of pharmacokinetics during aging and its correction].
    Zapadniuk VI
    Vrach Delo; 1984 Apr; (4):41-4. PubMed ID: 6741050
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.
    Eckert HG; Badian MJ; Gantz D; Kellner HM; Volz M
    Arzneimittelforschung; 1984; 34(10B):1435-47. PubMed ID: 6097271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Practical problems of pharmacokinetics].
    Berkhin EB
    Klin Med (Mosk); 1984 Nov; 62(11):11-7. PubMed ID: 6521365
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics in the 1980s.
    Balant LP
    Clin Ther; 1984; 6(2):112-24. PubMed ID: 6705009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys.
    Radulovic LL; Türck D; von Hodenberg A; Vollmer KO; McNally WP; DeHart PD; Hanson BJ; Bockbrader HN; Chang T
    Drug Metab Dispos; 1995 Apr; 23(4):441-8. PubMed ID: 7600909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologic factors in selecting human volunteers for drug studies.
    Azarnoff DL
    Clin Pharmacol Ther; 1972; 13(5):796-802. PubMed ID: 5054324
    [No Abstract]   [Full Text] [Related]  

  • 35. Studies on pharmacokinetics and biotransformation of oxepinac in mouse, rat, dog and man.
    Hakusui H; Suzuki W; Takegoshi T; Saito T; Sano M
    Arzneimittelforschung; 1978; 28(3):456-61. PubMed ID: 580756
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics: dose-dependent changes.
    Browne TR; Greenblatt DJ; Evans JE; Szabo GK; Evans BA; Schumacher GE
    J Clin Pharmacol; 1986; 26(6):463-8. PubMed ID: 3734138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primer on clinical pharmacokinetics.
    Bauer LA
    Am J Hosp Pharm; 1983 Oct; 40(10):1637-41. PubMed ID: 6638025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
    Sugiyama Y; Iwatsubo T; Ueda K; Ito K
    J Toxicol Sci; 1996 Dec; 21(5):309-16. PubMed ID: 9035043
    [No Abstract]   [Full Text] [Related]  

  • 39. Stable isotopes in pharmacology studies: present and future.
    Browne TR
    J Clin Pharmacol; 1986; 26(6):485-9. PubMed ID: 3525614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Geriatric polypharmacy.
    Williams L; Rush DR
    Hosp Pract (Off Ed); 1986 Feb; 21(2):109-12, 115-20. PubMed ID: 3081527
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.